Phase 2 clinical trials are ongoing in patients with anti-LGI1 encephalitis (NCT04875975) and myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (NCT05063162). This evidence concerns the gene MOG and encephalitis.